ADVB Advanced Biomed Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1941029 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY279.7%
TTM EPS YoY244.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE85.0%
ROA63.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.25x
Accruals ratio79.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | — | — | $243,226 | $186,331 | $235,992 | $234,225 | $219,966 | $212,397 |
| SG&A expense | $973,931 | $3.98M | $276,610 | $210,311 | $147,155 | $611,377 | $347,541 | $67,667 |
| Operating income | -$973,931 | — | — | — | -$147,155 | — | — | — |
| Pretax income | -$989,054 | -$12.52M | -$488,942 | $7.00M | -$147,155 | $675,636 | -$1.20M | -$579,494 |
| Net income | -$989,054 | $694,999 | -$488,942 | $6.86M | -$386,901 | -$701,611 | -$1.38M | -$907,904 |
| EBITDA | — | — | — | — | -$99,163 | — | — | — |
| EPS (basic) | -0.60 | — | -0.38 | 0.31 | -0.36 | — | -1.35 | -0.05 |
| EPS (diluted) | -0.60 | — | -0.38 | 0.31 | -0.36 | — | -1.35 | -0.05 |
| Weighted avg. shares (diluted) | 1.65M | — | 1.28M | 21.64M | 1.08M | — | 1.02M | 20.00M |
| Balance sheet | ||||||||
| Cash & equivalents | $213,995 | $385,535 | $2.60M | $2.60M | $12,644 | $31,139 | $3.18M | $2.65M |
| Current assets | $12.87M | $13.75M | $10.53M | $10.73M | $5.84M | $22.38M | $7.73M | $3.14M |
| PP&E, net | — | — | $87,280 | $97,100 | $281,270 | $125,184 | $355,274 | $401,007 |
| Intangibles | — | — | — | — | — | — | $20,325 | $50,516 |
| Total assets | $12.90M | $13.75M | $10.65M | $10.85M | $6.24M | $22.86M | $8.29M | $4.50M |
| Current liabilities | $1.59M | $1.47M | $1.43M | $1.25M | $3.04M | $19.24M | $4.11M | $3.83M |
| Total liabilities | $1.61M | $1.47M | $1.44M | $1.37M | $3.24M | $19.38M | $4.16M | $3.89M |
| Shareholders' equity | $11.29M | $12.28M | $9.21M | $9.48M | $3.00M | $3.48M | $4.13M | $619,032 |
| Shares outstanding | 1.65M | 1.65M | 1.38M | 21.64M | 21.64M | 1.08M | 21.64M | 20.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$171,464 | -$583,268 | -$239,775 | -$513,558 | -$610,342 | -$1.54M | -$3.41M | -$841,841 |
| Capital expenditure | — | — | $1,264 | $12,906 | $1,771 | $20,149 | $2,215 | -$10,692 |
| Free cash flow | — | — | -$241,039 | -$526,464 | -$612,113 | -$1.56M | -$3.41M | -$831,149 |
| Investing cash flow | — | -$2.49M | -$1,264 | -$12,906 | -$1,771 | -$20,149 | -$2,215 | $10,692 |
| Financing cash flow | — | $936,756 | $268,277 | $315,477 | $447,462 | -$765,466 | $5.90M | $408,286 |
| Depreciation & amortization | — | — | $9,326 | $14,462 | $47,992 | $275,865 | $22,507 | $21,983 |
Free plan shows the latest 8 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.